Literature DB >> 21911718

TACE and sorafenib: a good marriage?

Ghassan K Abou-Alfa.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21911718     DOI： 10.1200/JCO.2011.37.9651

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

3.  Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.

Authors:  Guang-Zhi Wang; Wei Zhang; Zhu-Ting Fang; Wen Zhang; Min-Jie Yang; Guo-Wei Yang; Shuo Li; Lian Zhu; Li-Li Wang; Wei-Sheng Zhang; Rong Liu; Sheng Qian; Jian-Hua Wang; Xu-Dong Qu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-23       Impact factor: 4.553

4.  Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ali A Haydar; Deborah Mukherji; Walid Faraj; Mohammad Khalifeh; Bedros Taslakian; Zeinab Abou Yehia; Sally Temraz; Karen T Brown; Ghassan K Abou-Alfa; Ali Shamseddine
Journal:  Gastrointest Cancer Res       Date:  2014-05

5.  Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.

Authors:  Jiaping Li; Fujun Zhang; Jianyong Yang; Yingqiang Zhang; Yu Wang; Wenzhe Fan; Yonghui Huang; Wei Wang; Henry Ran; Shi Ke
Journal:  Target Oncol       Date:  2014-10-08       Impact factor: 4.493

Review 6.  Advanced Hepatocellular Cancer: the Current State of Future Research.

Authors:  Louise C Connell; James J Harding; Ghassan K Abou-Alfa
Journal:  Curr Treat Options Oncol       Date:  2016-08

7.  Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.

Authors:  Lei Zhang; Jun-Hui Sun; Zhong-Heng Hou; Bin-Yan Zhong; Zhi-Ping Yan; Cai-Fang Ni; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Peng Huang; Shen Zhang; Zhi Li; Xiao-Li Zhu
Journal:  Cardiovasc Intervent Radiol       Date:  2020-09-23       Impact factor: 2.740

8.  Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.

Authors:  Zhexuan Wang; Enxin Wang; Wei Bai; Dongdong Xia; Rong Ding; Jiaping Li; Qiuhe Wang; Lei Liu; Junhui Sun; Wei Mu; Hui Zhao; Xingnan Pan; Guoliang Shao; Xiaoli Zhu; Guowen Yin; Haibin Shi; Jianbing Wu; Zhengyu Lin; Shufa Yang; Jueshi Liu; Wenhui Wang; Xu Zhu; Yong Lv; Jing Li; Hui Chen; Wenjun Wang; Kai Li; Xulong Yuan; Tanlei Yu; Jie Yuan; Xiaomei Li; Jing Niu; Zhanxin Yin; Jielai Xia; Daiming Fan; Guohong Han
Journal:  Liver Cancer       Date:  2020-02-19       Impact factor: 11.740

Review 9.  Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Tatsuo Ueda; Ken Nakazawa; Shiro Onozawa; Daisuke Yasui; Shin-ichiro Kumita
Journal:  ScientificWorldJournal       Date:  2013-03-27

Review 10.  Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Qi-Han Fu; Qi Zhang; Xue-Li Bai; Qi-Da Hu; Wei Su; Yi-Wen Chen; Ri-Ga Su; Ting-Bo Liang
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-26       Impact factor: 4.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.